Position
Creative Planning in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $23K$771.88 → $772.64
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 30.1K | $23.3M | — | — | — | 0.0% |
| Q1 2026 | 40.2K | $31M | $772.64 | $23K | $7.74M | 0.0% |